Actively Recruiting
Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease
Led by Fondazione Epatocentro Ticino · Updated on 2025-07-09
200
Participants Needed
1
Research Sites
384 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to establish a unified cohort for retrospective and prospective high quality baseline and follow-up data registration of patients with a diagnosis of NAFLD/NASH/MAFLD, according to standardized criteria. This will allow future studies aimed at elucidate clinical presentation, natural history, response to treatment, genetic and metabolic risk factors, treatment options and outcomes of the disease. The cohort will allow investigators to carry out genetic, serological, microbiologic and immunological studies.
CONDITIONS
Official Title
Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant must be 18 years of age or older at the time of signing the informed consent
- Participant must be willing to sign the informed consent form and complete all study visits and procedures
- Have a diagnosis of NAFLD, NASH, or MAFLD confirmed by either liver biopsy, liver imaging (ultrasound, CT scan, MRI, or CAP), or metabolic syndrome with liver fibrosis or cirrhosis without another diagnosis
- Metabolic syndrome diagnosis includes one or more of: abdominal obesity (waist circumference >35 inches for women, >40 inches for men), high blood pressure (130/80 mm Hg or higher), impaired fasting blood glucose (≥100 mg/dL), high triglycerides (>150 mg/dL), or low HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women)
- Alcohol consumption less than 21 units per week for males or less than 14 units per week for females in the 6 months before enrollment
- No history of excessive alcohol consumption in the 5 years before enrollment
You will not qualify if you...
- Diagnosis of type I diabetes mellitus
- Presence of another liver disease
- Use of drugs that may cause liver fat buildup in the last 12 months on more than half the days, including high-dose corticosteroids (>20mg prednisone equivalent), amiodarone, methotrexate, tamoxifen, tetracycline, high-dose estrogens, or valproic acid
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Epatocentro Ticino
Lugano, Canton Ticino, Switzerland, 6900
Actively Recruiting
Research Team
A
Andreas Cerny, Prof. Dr. med
CONTACT
M
Maurizia Bissig
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here